

## REMARKS

By this amendment, claims 1, 3 and 13-16 have been amended and claims 7, 8, 10 and 17 have been cancelled. The claims have been modified by deletion of subject matter covered in the parent cases. Minor changes to delete extraneous parentheses have also been made.

Support for the amendment to claim 13 may be found in the specification at page 87, lines 6-30 *inter alia*.

Typographical and grammatical corrections have also been made throughout the specification.

No amendment of inventorship is necessitated by these amendments.

Early allowance of the claims is requested. Should the Examiner believe that a conference with Applicants' Attorney would advance prosecution of this application, the Examiner is respectfully invited to call Applicants' Attorney.

Respectfully submitted,

Dated: January 13, 2004

(847) 383-3391

(847) 383-3372

Elaine M. Ramesh

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Mark Chao, Ph.D., Reg. No. 37,293

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA